TrialCancer research communications2025

A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years.

Eric D Eisenmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.